16:25:40 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2023-05-05 17:05:46
Moss, 5 May 2023

Gentian Diagnostics ASA ("Gentian") has today been notified that the following
transaction has been completed by a close associate of a primary insider in
Gentian:

Holta Invest AS ("Holta"), a close associate of primary insider Espen Tidemann
Jørgensen, board member, is in the process of simplifying its group structure.
The re-organization will result in its ownership in Gentian, currently owned
indirectly through Holta Life Sciences AS and Holta Horisont AS, will be owned
directly by Holta. Holta's total ownership in Gentian will remain unchanged as a
result of the re-organization.

Firstly, Holta Horisont AS has today sold all its 13,800 shares in Gentian to
Holta Invest AS at a share price of NOK 47.50 per share.

Secondly, Holta Life Sciences AS has today sold all its 1,214,702 shares in
Gentian to Holta Invest AS at a share price of NOK 47.50 per share.

Following the above transactions Holta Horisont AS and Holta Life Sciences AS
hold no shares in Gentian. Holta's total ownership of 1,228,702 shares (7,97%)
in Gentian has not changed as result of the above transactions.

IR Contact: Njaal Kind, Group CFO, njaal.kind@gentian.no, +47 91 90 65 25

Please refer to the attached notification of trading for further details. This
information is subject to the disclosure requirements in the EU Market Abuse
Regulation and section 5-12 of the Norwegian Securities Trading Act.